The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > ORGANIZATION
ORGANIZATION
- JMA’s New Pharma Affairs Exec Wants More Stringent Rules on Sakigake, Conditional Approval
August 11, 2020
- Bayer Yakuhin President Heike Prinz Elected New EFPIA Japan Chief
August 3, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- Pharmacist Group Says Drug Price Survey This Year “Utterly Unacceptable”
July 21, 2020
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
- Trade Group Urges Drug Makers to Fully Provide Info on Stock-Outs, Supply Curbs
July 20, 2020
- JPMA Reiterates It’s Not the Right Time for Off-Year Drug Price Survey
July 17, 2020
- Number of Contract Sales Reps Up 10.8% to 3,445, with New Drug Launches
July 17, 2020
- JMA Chief Says Off-Year Price Survey “Technically Impossible”, JPA President Meets PM
July 16, 2020
- Japan Red Cross Presses ahead with Joint Purchase of Drugs Selected under Formularies at Group Hospitals
July 15, 2020
- AMR Action Fund Would Help Deal with Threat While We Still Have Time: IFPMA Vice Pres.
July 14, 2020
- JMA Reiterates Concerns for Off-Year Drug Price Survey after Govt’s Honebuto Draft Revealed
July 13, 2020
- Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Expand Self-Medication Tax Break to Cover All Non-Prescription Drugs: OTC Group
July 6, 2020
- Stop Patient Enrollment in Avigan Studies: Drug Damage Watchdog
July 3, 2020
- Drug Makers Joining Forces to Share Manufacturing Capacities, Accelerate COVID-19 Programs: PhRMA CMO
July 2, 2020
- COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
- Generic Use Rate at 76.9% in FY2019, 78.5% in Jan.-March 2020: JGA
July 1, 2020
- Toshio Nakagawa Elected as New Chief of Japan Medical Association
June 29, 2020
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…